From clinical application to cognitive enhancement: The example of methylphenidate
TL;DR: In this review different aspects concerning the use of MPD have been approached, data showing its abuse among college students are given, when the drug is prescribed short term beneficial effects and side effects are provided; moreover studies on animal-models suggesting long lasting negative effects on healthy brains are discussed.
read more
Abstract: Methylphenidate (MPD) is a central nervous system (CNS) stimulant, which belongs to the phenethylamine group and is mainly used in the treatment of attention deficit hyperactive disorder (ADHD). However, a growing number of young individuals misuse or abuse MPD to sustain attention, enhance intellectual capacity and increase memory. Recently, the use of MPD as a cognitive enhancement substance has received much attention and raised concerns in the literature and academic circles worldwide. The prescribing frequency of the drug has increased sharply as consequence of the more accurate diagnosis of the ADHD and the popularity of the drug itself due to its beneficial short-term effect. However, careful monitoring is required, because of possible abuse. In this review different aspects concerning the use of MPD have been approached. Data showing its abuse among college students are given, when the drug is prescribed short term beneficial effects and side effects are provided; moreover studies on animal-models suggesting long lasting negative effects on healthy brains are discussed. Finally, emphasis is given to the available formulations and pharmacology.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Methylphenidate Enhances Working Memory by Modulating Discrete Frontal and Parietal Lobe Regions in the Human Brain
Mitul A. Mehta,Adrian M. Owen,Barbara J. Sahakian +2 more
- 01 Jan 2002
TL;DR: This paper investigated changes in regional cerebral blood flow (rCBF) induced by methylphenidate during performance of a self-ordered spatial working memory task to define the neuroanatomical loci of the beneficial effect of the drug.
547
Methylphenidate for children and adolescents with autism spectrum disorder.
TL;DR: The meta-analysis suggested that high-dose methylphenidate had a significant and clinically relevant benefit on hyperactivity, as rated by teachers and parents and overall ASD, and overall quality of life.
The emerging roles of human trace amines and human trace amine-associated receptors (hTAARs) in central nervous system
Muhammad Zahid Khan,Waqas Nawaz +1 more
TL;DR: Findings are discussed that provide insights into the functional roles of human trace amines (including P-Octopamine, β phenylethylamine, Tryptamine, Tyramine, Synephrine, 3-Iodothyronamine, N-Methyltyramine) in brain and the known functions of human Trace amine receptors in brain.
93
How Realistic Are the Scientific Assumptions of the Neuroenhancement Debate? Assessing the Pharmacological Optimism and Neuroenhancement Prevalence Hypotheses.
Stephan Schleim,Boris B. Quednow +1 more
TL;DR: It is concluded that the pharmacological optimism hypothesis and neuroenhancement prevalence hypotheses have to be rejected and it is argued that the neuro enhancement debate should take the available evidence more into account.
Use of cognitive enhancers: methylphenidate and analogs.
TL;DR: Careful monitoring and systematic control of methylphenidate analogs should be undertaken to reduce the uprising threat, and education efforts should be made among high-risk populations.
46
References
Safety of medicines used for ADHD in children: a review of published prospective clinical trials
Antonio Clavenna,Maurizio Bonati +1 more
TL;DR: Few studies evaluated the long-term safety of drugs for ADHD, andeterogeneity in follow-up duration and in data reporting made comparing different studies and drugs difficult.
Single‐ and Multiple‐Dose Pharmacokinetics of an Oral Once‐a‐Day Osmotic Controlled‐Release OROS® (methylphenidate HC1) Formulation
TL;DR: The bioavailability of methylphenidate and PPA from OROS® (methylphenidate HCl) relative to the IR and SR formulations was complete and the dose‐normalized methyl phenidate Cmax for OROS®, (methyl phenidate H cl) was significantly lower than for IR andSR methylphenidates.
•Journal Article
Pharmacotherapy of attention-deficit/hyperactivity disorder in adults
TL;DR: These studies have demonstrated the efficacy of methylphenidate, pemoline, and monoamine oxidase-B (MAO-B) inhibitors when administered to adult ADHD patients; a robust response was produced in 60% of the patients.
•Journal Article
Increased methylphenidate usage for attention deficit disorder in the 1990s.
TL;DR: The database findings presented serve to correct exaggerated media claims of a 6-fold expansion of methylphenidate treatment, although they do not clarify the issue of the appropriateness of this treatment.
•Journal Article
Pregnancy and delivery complications and treatment approach in attention deficit hyperactivity disorder
TL;DR: Pregnancy, delivery complications and treatment approach were evaluated in 153 cases diagnosed with attention deficit hyperactivity disorder in the State Hospital of Antalya and use of selective serotonin reuptake inhibitors in combined treatment and in cases with comorbidities is in agreement with the literature.